France will have to “adjust the pace of vaccinations” against coronavirus due to the expected “sharp decline” in deliveries of the Pfizer/Biontech vaccine in the coming weeks, a source within the executive said.
These delays, due to work on a production chain in Belgium, do not, however, call into question “the overall deployment of the vaccine campaign” in France, it is said from the same source. This country, which has already received 1.5 million doses of Pfizer vaccine, was expecting another 520,000 next week.
As of Thursday evening, 318,000 people had received a first injection of serum, with a target of 1 million by the end of January.
The revision of this progress board will take place “as soon as France knows exactly the level of future deliveries”, said the same source, stating however that France had “anticipated possible delays” in its management of deliveries. The stock should therefore allow for continued vaccinations, but at a more measured rate than expected.
France, like others of its European neighbours, is the target of criticism of the slow pace of the campaign.
The US laboratory Pfizer confirmed on Friday that its deliveries of Covid vaccines outside the United States would slow down in late January-early February, with time to change the manufacturing process and thus increase the pace for the following weeks.
In the end, despite this slowdown in deliveries, European Commission President Ursula von der Leyen assured that she had Pfizers guarantee that all doses expected by the EU in the first quarter would be well received.
These counterremps, which triggered the wrath of several European countries, will not affect the United States, the US laboratory said.
France also benefits from doses of Moderna vaccine, in small quantities for the time (52,000 to date).
By CCEiT (AFP)